An index of captured practitioner sources, not a completed evidence summary. Unchecked figures and empty sections are omitted. See the library review status.
Source summary generated July 17, 2026; this date does not indicate completed review.
Quotes from three independent practitioners, with their sources. Research context only.
What it is and how it works
From the published literature on Testosterone; the papers are listed at the end. Research summary, not a recommendation.
What it is
Testosterone is not a peptide: it is a steroid hormone made from cholesterol, mainly by the testes in men and in smaller amounts by the ovaries and adrenal glands in women. It drives male sexual development and maintains libido, muscle, bone and red-blood-cell production in adults. Testosterone replacement therapy (TRT) uses FDA-approved testosterone products (injections, gels, patches, pellets and oral forms) to treat male hypogonadism, meaning low testosterone caused by disease of the testes, pituitary or hypothalamus.
How it works
Testosterone acts mainly through the androgen receptor, a protein inside cells that, once testosterone binds, switches on genes for muscle growth, red-blood-cell production, hair growth and sexual function. In some tissues it is converted by the enzyme 5-alpha reductase into the stronger androgen dihydrotestosterone (DHT), and in fat, bone and brain it is converted by the enzyme aromatase into estradiol, an estrogen that is needed for bone health and libido in men. The brain controls natural production through LH and FSH, pituitary hormones that tell the testes to make testosterone and sperm. Taking testosterone from outside switches off LH and FSH, so the testes' own testosterone and sperm production fall, which is why TRT reduces fertility.
What it has been studied for
Sexual function, mood and physical function in older men with low testosterone (randomized trials and meta-analysis)
Cardiovascular safety in men with hypogonadism and heart risk (large randomized trial)
Fracture risk in men with hypogonadism (large randomized trial)
Preventing type 2 diabetes in men with prediabetes (randomized trial)
Diagnosis and treatment standards for male hypogonadism (clinical practice guideline)
Strength of the evidence
Approved drugMultiple FDA-approved testosterone products exist for male hypogonadism, supported by large randomized placebo-controlled trials.
What the literature reports on safety
In trials and FDA labels the main risks were a rise in red-blood-cell concentration (hematocrit) that can thicken the blood, reduced sperm production and fertility, acne, breast enlargement and worsening of untreated sleep apnea; the large TRAVERSE trial found no increase in heart attacks or strokes but more atrial fibrillation, acute kidney injury and pulmonary embolism, and a companion analysis found more fractures, not fewer. The Endocrine Society guideline advises against treatment in men planning fertility and in men with breast or prostate cancer, and testosterone gels carry an FDA boxed warning about transfer to children and women by skin contact. Testosterone is a Schedule III controlled substance in the United States and is prohibited in sport by the World Anti-Doping Agency.
Review · Bhasin S, Brito JP, et al. · Journal of Clinical Endocrinology and Metabolism (2018) · PMID 29562364
Set the standard that hypogonadism be diagnosed only with symptoms plus repeatedly low morning testosterone, and listed the conditions in which treatment should be avoided.
Review · Hudson J, Cruickshank M, et al. · Lancet Healthy Longevity (2023) · PMID 37804846
Across 35 trials with 5601 men aged 40 and over with low testosterone, treatment produced a clinically meaningful improvement in mild erectile dysfunction regardless of age or obesity.
Randomized trial · Snyder PJ, Bhasin S, et al. · New England Journal of Medicine (2016) · PMID 26886521
In symptomatic men aged 65 and over, a year of testosterone moderately improved sexual function and somewhat improved mood, but did not improve vitality or walking distance.
Randomized trial · Lincoff AM, Bhasin S, et al. · New England Journal of Medicine (2023) · PMID 37326322
In men with hypogonadism and heart disease or high heart risk (TRAVERSE), major cardiac events occurred in 7.0% on testosterone versus 7.3% on placebo, but atrial fibrillation, kidney injury and pulmonary embolism were more common.
Randomized trial · Snyder PJ, Bauer DC, et al. · New England Journal of Medicine (2024) · PMID 38231621
In 5204 middle-aged and older men, clinical fractures occurred in 3.50% on testosterone versus 2.46% on placebo, so treatment did not lower fracture risk.
Randomized trial · Wittert G, Bracken K, et al. · Lancet Diabetes and Endocrinology (2021) · PMID 33338415
In 1007 men with prediabetes or new diabetes in a lifestyle program, diabetes-range glucose at two years occurred in 12% on testosterone versus 21% on placebo, though rising hematocrit could limit treatment.
Sources checked: PubMed/PMC (E-utilities esummary and abstracts on every PMID), written 2026-11-06.
Answers are generated from captured sources and may omit context or contain errors. Check the supporting passages.
What have the teachers said about Testosterone? Ask what it is, what they say it does, or where they discuss it. Questions about doses or personal use: ask your own clinician.
AI chat. To generate a reply, your question and recent chat history may be processed by Cloudflare Workers AI, Groq, Google Gemini or OpenRouter, depending on availability. Keep personal health details out of the chat and check the cited sources. Research use only; not medical advice.
All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.